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Abstract
Leishmania donovani causes visceral leishmaniasis (VL), which is typically fatal without
treatment. There is substantial variation between individuals in rates of disease progression,
response to treatment and incidence of post-treatment sequelae, specifically post-kala-azar
dermal leishmaniasis (PKDL). Nevertheless, the majority of infected people are asymptom-
atic carriers. Hamsters and mice are commonly used as models of fatal and non-fatal VL,
respectively. Host and parasite genetics are likely to be important factors, but in general the
reasons for heterogeneous disease presentation in humans and animal models are poorly
understood. Host microbiota has become established as a factor in cutaneous forms of
leishmaniasis but this has not been studied in VL. We induced intestinal dysbiosis in mice
and hamsters by long-term treatment with broad-spectrum antibiotics in their drinking water.
There were no significant differences in disease presentation in dysbiotic mice. In contrast,
dysbiotic hamsters infected with L. donovani had delayed onset and progression of weight
loss. Half of control hamsters had a rapid progression phenotype compared with none of the
ABX-treated animals and the nine-month survival rate was significantly improved compared
to untreated controls (40% vs. 10%). Antibiotic-treated hamsters also had significantly less
severe hepatosplenomegaly, which was accompanied by a distinct cytokine gene expres-
sion profile. The protective effect was not explained by differences in parasite loads or hae-
matological profiles. We further found evidence that the gut-liver axis is a key aspect of fatal
VL progression in hamsters, including intestinal parasitism, bacterial translocation to the
liver, malakoplakia and iron sequestration, none of which occurred in non-progressing
murine VL. Diverse bacterial genera were cultured from VL affected livers, of which
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Rodentibacter was specifically absent from ABX-treated hamsters, indicating this patho-
biont may play a role in promoting disease progression. The results provide experimental
support for antibiotic prophylaxis against secondary bacterial infections as an adjunct ther-
apy in human VL patients.
Author summary
Visceral leishmaniasis (VL) is a potentially fatal neglected infectious disease that is wide-
spread in South Asia, East Africa, South America and the Mediterranean region. VL is
caused by infections with the protozoan parasite Leishmania donovani. Infected people
may remain asymptomatic or progress, at variable rates, to develop VL disease affecting
the liver, spleen and blood. The reasons why clinical outcomes vary so much is not well
understood. We decided to investigate whether a host’s gut microbiota might be a relevant
factor. We treated mice and hamsters with antibiotics to disrupt their gut microbiota and
then infected them with L. donovani. No effect was observed in mice, however, treated
hamsters had slower onset and progression of VL, less severe enlargement of the liver and
spleen, and had a reduced mortality rate. This was accompanied by alterations in the levels
of key immune response factors. We also found novel aspects of symptomatic VL in ham-
sters relating to the gut and its microbiota. Specifically, the gut tissues themselves were
parasitized by L. donovani and liver tissues became co-infected with both L. donovani and
Gram negative bacteria originating from the gut. Overall, our findings support the inclu-
sion of anti-bacterial therapy as part of VL treatment strategies.
Introduction
Kala-azar or visceral leishmaniasis (VL) is caused by infection with members of the Leish-
mania donovani species complex (L. donovani, L. infantum/chagasi). These parasitic protozoa
are transmitted to humans and reservoir mammals during blood feeding by infected female
sand flies. VL is endemic in large parts of South Asia, East Africa, Latin America and the Medi-
terranean region. A recent report by WHO on the 14 high-burden countries (>100 cases/year)
shows a decrease in overall cases reported, down from an average of 58,000 new cases reported
per year between 2004–2008, to 30,758 new cases in 2014, with underreporting estimated to be
from 1.2- to 4-fold [1]. Symptomatic VL is typically characterised by gross enlargement of the
spleen and liver, pancytopaenia and hypergammaglobulinaemia, and is considered fatal with-
out anti-parasitic chemotherapy [2]. This pathology is associated with high parasite loads and
chronic inflammatory responses in the visceral organs, lymph nodes and bone marrow. Death
is usually attributed to factors secondary to L. donovani infection, including immunosuppres-
sion, haemorrhages and opportunistic infections [3]. The rate of progression varies substan-
tially between individuals, as does the incidence of post-kala-azar dermal leishmaniasis
(PKDL, a post-treatment complication) in different regions [4]. Moreover, 80–95% of L. dono-
vani infections are thought to be subclinical or asymptomatic [5, 6]. This heterogeneity of VL
outcomes is thought to reflect both genetic and environmental factors [7–9]. Some specific
determinants of susceptibility have been identified, for example host nutritional status [10]
and polymorphisms in the HLA locus [11], however, the mechanistic basis of fatal progression
is poorly understood.
PLOS PATHOGENS Gastrointestinal factors in visceral leishmaniasis pathogenesis
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008456 April 13, 2020 2 / 23
Program of the NIAID, National Institutes of Health
(https://irp.nih.gov/). The funders had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Hamsters and susceptible mouse strains (e.g. C57BL/6, BALB/c) are the most widely used
experimental models of L. donovani infection. The hamster model recapitulates many features
of symptomatic human VL, including hepatosplenomegaly and haematological defects. It is
characterised by progressively increasing parasite loads in target organs and develops into a
cachexia-like syndrome, which becomes fatal after several months of infection [12, 13].
Whether the causes of death in hamsters are similar to those in human VL cases is unclear. Of
note, opportunistic pathogens equivalent to those affecting human patients are absent from
vivaria with specific pathogen-free (SPF) environments. Murine VL is not fatal; it features sta-
ble, chronic infection of the spleen causing splenomegaly but parasitism of the liver is slowly
resolved by effective immune responses [14, 15]. One reason for the effective control of L.
donovani infection in mice compared to hamsters is the relatively enhanced induction of pro-
tective iNOS activity in infected murine macrophages [16]. Hamster macrophages appear to
be hypo-responsive to IFN-γ and are more likely to adopt a permissive state characterised by
high STAT6-dependent arginase I expression [17]. However, it is not clear whether the inter-
species difference in this pathway can fully explain the lethality of L. donovani infection in
hamsters.
This study aimed to address the hypothesis that the host microbiota is a factor affecting dis-
ease outcomes in experimental VL models. Commensal skin bacteria have been shown to
influence the host-parasite interaction and pathology in models of cutaneous leishmaniasis
(CL). Specifically, germ-free mice inoculated with L. major or L. amazonensis have been
reported to develop smaller skin lesions [18–20], although others have observed larger lesions
[21]. These data generally support a pro-inflammatory function for the microbiota in CL. To
our knowledge there are no comparable data for VL. A key difference is that unlike in CL, the
pathologies associated with chronic L. donovani infection do not occur in sites where com-
mensals are normally present. Nevertheless, the impact of the gut microbiota on immune
responses in distant sites is becoming increasingly apparent [22].
We disrupted the normal intestinal microbiota of mice and hamsters using antibiotics and
studied the effect on L. donovani infection. Murine VL was unaffected, however, a significant
improvement of outcomes was observed in hamsters. Fatal progression was accompanied by
evidence of bacterial translocation from the gut to the liver, which exacerbated hepatic pathol-
ogy. The results provide experimental support for clinical trials incorporating antibiotic pro-
phylaxis against secondary bacterial infections as an adjunct therapy in human VL patients.
Results
Effect of antibiotic-induced dysbiosis on VL in mice
To investigate a potential role for the host microbiota in the mouse model of VL, we treated
C57BL/6 mice with broad-spectrum antibiotics via their drinking water prior to i.v. injection
with 107 L. donovani strain 1S (Ld1S) metacyclic promastigotes and throughout the following
infection (Fig 1A). We observed that a cocktail of ampicillin, vancomycin and neomycin
(ABX) led to a strong and sustained depletion of gut microbiota, as measured by the 16S
rDNA copy number in faeces (Fig 1B). We tested the effect of metronidazole as a fourth antibi-
otic [23] but this led to reduced fluid intake and was associated with less efficient microbiota
depletion. Profound dysbiosis in ABX-treated animals was evidenced macroscopically by gross
enlargement of the caecum, a result of the loss of bacterial species required for normal fermen-
tation of dietary carbohydrates (Fig 1C). This effect was equivalent in both control uninfected
and Ld1S-infected animals.
ABX-treated mice had a larger average spleen size at 35, 56 and 84 days after Ld1S infections
but this difference was not significant due to substantially increased variation in the treated
PLOS PATHOGENS Gastrointestinal factors in visceral leishmaniasis pathogenesis
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008456 April 13, 2020 3 / 23
groups (Fig 1D). The increased splenomegaly observed in a subset of individual ABX-treated
mice may indicate an effect associated with differential dysbiosis. No effect was observed with
respect to hepatomegaly (Fig 1E) and ABX-treatment did not lead to differences in spleen or
liver weights in uninfected controls (Fig 1D and 1E). Parasite loads in the liver and spleen were
equivalent in both groups and conformed to the expected pattern of stable chronic infection in
the spleen and gradually declining parasite loads in the liver (Fig 1F). Overall, these data show
that disruption of the normal intestinal microbiota had no significant impact on the mouse
model of non-progressing VL.
Antibiotic-induced dysbiosis ameliorates VL in hamsters
Unlike the mouse model, our standard model of hamster VL (3 x 107 L. donovani 1S metacyc-
lic promasitgotes injected intra-cardially) is progressive and usually results in death within 6
Fig 1. Effects of oral antibiotic treatment on outcomes in a mouse model of non-progressing visceral leishmaniasis. (A) Experimental design; (B) qPCR
analysis of bacterial 16S rDNA content in mouse faecal pellets at different times before (n = 21) and during oral antibiotic regimens (n = 3–9), including a
germ-free control (n = 1). Lines show medians and dashed line shows the detection limit (mean + 2 standard deviations of negative extraction controls); (C,
D, E, F) Caecum (C), spleen (D) and liver (E) weights, and parasite loads (F) measured at necropsy at the indicated times after infection with Leishmania
donovani strain 1S (Ld1S) and maintained on drinking water containing antibiotic cocktail (ABX) compared with naïve controls and no ABX controls, dpi,
days post-infection, n = 2–5 per group.
https://doi.org/10.1371/journal.ppat.1008456.g001
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months. This model is considered to better reflect symptomatic human VL than the mouse
[24]. We therefore conducted experiments to compare VL outcomes in ABX-treated and
untreated control Ld1S-infected hamsters up to a maximum of nine months (Fig 2A). Contin-
uous ABX treatment led to a more moderate faecal microbiota depletion than was seen in
mice and the 16S rDNA copy numbers returned to normal levels by the time that the hamster’s
humane end-points were reached (Fig 2B). Nevertheless, massive enlargement of the caeca of
ABX-treated hamsters indicated that dysbiosis was maintained during the experiments (Fig
2C).
Hamsters in both experimental groups were susceptible to infection and had similar L.
donovani-specific IgG titres (Fig 2D). In the hamster VL model, weight loss is considered a
proxy for disease progression, and we designated a 20% loss in original body weight as the
humane endpoint. As expected, the onset of VL-related weight loss in hamsters infected with
Ld1S and given control water occurred at 2 months post-infection (p.i.) (Fig 2E). The progres-
sion of disease occurred very rapidly in half of these animals, with terminal humane endpoints
occurring after 112–132 days of infection (Fig 2F and 2G). End-points were reached by the
remaining slower-progressing animals between 6 and 8 months p.i. (Fig 2F). This variability is
likely attributable to the outbred nature of experimental hamsters. The onset of weight loss
was significantly delayed in ABX-treated hamsters (Fig 2E) and there was a strong negative
correlation between caecum enlargement (dysbiosis) and the severity of weight loss (disease
progression) specifically in this group and not untreated controls (Fig 2H). Weight loss was
less marked in male hamsters but ABX treatment still had a significant effect on weight profiles
Fig 2. Oral antibiotic treated hamsters have delayed VL disease progression and reduced mortality. (A) Experimental design; (B) qPCR analysis of bacterial 16S
rDNA content in hamster faecal pellets at different times (x-axis) before and during oral antibiotic treatment (ABX); Leishmania donovani (Ld) infections were initiated at
4 weeks of ABX treatment. Lines show medians. (C) Representative images of viscera at humane end-point and caecum weights at 12 weeks post-infection in Leishmania
donovani (Ld)-infected hamsters maintained on drinking water containing antibiotic cocktail (ABX) compared with naïve controls and no ABX controls; arrows indicate
caecum. (D) L. donovani whole cell lysate-reactive IgG antibody titres measure by ELISA (OD, optical density), compared by one-way ANOVA. (E,F) Weight change over
time, data shown for means (E) and individual animals (F) where dashed red line marks humane end-point. (G) Survival curve for Ld-infected hamsters treated with ABX
or not, Gehan-Breslow-Wilcoxon test p = 0.019. (H) Pairwise comparison and Pearson correlation tests of individual animal’s caecum weight and post-infection change
in body weight. Experiments using VL onset end point (B, C, D, E, H) n = 5–16 per group; experiments using humane/maximum end-points (F, G), n = 10 per group.
https://doi.org/10.1371/journal.ppat.1008456.g002
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(S1 Fig). The rate of survival for nine months was significantly better (40% vs. 10%, p = 0.036,
log-rank test) (Fig 2G) and those treated hamsters that did succumb to the infection were all
slow-progressors (Fig 2F). Therefore, ABX-treatment was associated with a dramatic improve-
ment of outcomes in Ld1S-infected hamsters.
Infection and tissue remodelling
Enlargement of the spleen is a key feature of human VL and splenic aspirates are widely used
to diagnose VL patients [25]. At 12 weeks p.i. (a stage when control infected hamsters have
become symptomatic), we found that ABX-treated hamsters had significantly less severe
splenomegaly than hamsters given control water (Fig 3A), which was in keeping with the
weight loss and mortality results. Splenomegaly did not correlate with overall weight loss at
this stage of infection (Fig 3B). Confining the analysis to hamsters that were allowed to reach
their humane endpoint, we found that the spleens of longer surviving animals were typically
larger than in fast progressing ones and were significantly smaller in the ABX-treated group
(Fig 3C). Splenic remodelling is therefore not likely to be a direct cause of fatal disease progres-
sion in this model. We reasoned that improved outcomes in ABX-treated hamsters might be
associated with lower burden of L. donovani infection, but surprisingly this was not the case.
Spleen parasite loads at 12 weeks p.i. were not significantly different from control animals
either in terms of total number of parasites (Fig 3D) or the density of infection (Fig 3E). Para-
site loads did not show any association with weight loss at this time point (Fig 3F, S2 Fig) or
with survival time in the longer term (Fig 3G, S2 Fig), suggesting that other factors drive dis-
ease progression.
Failure to control L. donovani levels in the liver and enlargement of this organ are also key
features of both human VL and the fatal hamster model, whereas liver infection and pathology
resolve slowly in the non-progressing mouse model [12–14]. We found that hepatomegaly at
12 weeks p.i. was significantly less severe in ABX-treated hamsters than in untreated controls
(Fig 4A). There was no association between liver weight and overall weight loss, i.e. disease
progression, at this time point (Fig 4B). In the longer term, confining the analysis to hamsters
that had reached their humane endpoint, animals that suffered rapid fatal progression tended
to have less severe hepatomegaly in both experimental groups (Fig 4C). Irrespective of survival
time, ABX-treated animals had significantly smaller livers than untreated controls (Fig 4C). In
terms of parasite loads the findings mirrored the results for the spleen. Total numbers of liver
parasites (Fig 4D) and parasite density (Fig 4E) were equivalent at 12 weeks p.i. in the ABX-
treated and control groups, and these were not associated with disease progression rate (Fig
4F, S2 Fig). Liver infection was less intense in more rapidly progressing hamsters (Spearman
rank correlation r = 0.59, p = 0.028), but overall this parameter was not significantly different
between treated and untreated groups at survival end points (Fig 4G).
Overall, these data demonstrate that slower progression of VL and reduced tissue remodel-
ling in ABX-treated hamsters is not associated with lower parasite burdens in the spleen or
liver. More generally, they also indicate that neither parasite loads in, nor enlargement of,
these organs are significant correlates of fatal VL progression.
Disruption of haematological homeostasis
Haematological disorders and parasite persistence in bone marrow are common features of
human VL [26, 27] and we reasoned these could be relevant to disease amelioration in ABX-
treated hamsters. We detected high levels of L. donovani infection in bone marrow in hamsters
at 12 weeks p.i., but parasite loads were not significantly different in ABX-treated animals
compared to controls and they did not correlate with disease progression (S3 Fig). We next
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analysed leukocyte subsets in peripheral blood (Fig 5) and found that the frequency and abun-
dance of polymorphonuclear cells and eosinophils were significantly reduced in infected ham-
sters, while basophil levels were significantly increased. Leukocyte profiles were not
significantly altered by ABX-treatment at this time point. Analysis of the red blood cell com-
partment revealed pronounced anaemia in both ABX-treated and untreated, infected hamsters
at 12 weeks p.i., evidenced by significantly reduced erythrocyte numbers, haemoglobin levels
and packed cell volume (Fig 6A–6C). ABX-treated hamsters had a significantly lower mean
corpuscular volume than untreated controls (Fig 6D) possibly reflecting lower reticulocyte
production. Consistent with the observed anaemia, we found clear histological evidence of
iron sequestration in these hamsters’ livers (Fig 6E). The amount of sequestered iron showed
high intra-group variability and although the means were not significantly different between
ABX-treated and untreated controls, the most severe cases (Prussian blue scores> 6000) were
only seen in control hamsters.
Fig 3. Prolonged survival in antibiotic treated hamsters is associated with less severe splenomegaly despite equivalent or higher parasite loads. (A) Spleen weights
of hamsters at 12 weeks post-infection (p.i.) with L. donovani and given drinking water containing antibiotic cocktail (ABX) compared with uninfected naïve and
untreated controls; p-values are from one way ANOVA. (B) Pairwise comparison and Pearson correlation test of splenomegaly severity and change in body weight (proxy
for disease progression) at 12 weeks p.i. (C) Pairwise comparison between splenomegaly severity and time to humane end-point (fatal progression); p-value is from
comparison of linear regression slope elevations. (D,E) Total parasite loads (D) and infection intensities (E) in spleens after 12 weeks of infection, measured by limiting
dilution ex vivo culture assay. (F) Pairwise comparison and Pearson correlation test of spleen parasite densities and change in body weight (proxy for disease progression)
at 12 weeks p.i. (G) Pairwise comparison between spleen parasite density and time to humane end-point (fatal progression); p-value is from comparison of linear
regression slope elevations. In B-G data points are for individual hamsters treated with oral antibiotics (filled circles) and untreated controls (open circles). Analysis using
VL onset end point (A,D,E), n = 5–27 per group; analysis using humane/maximum end-points (C, G), n = 9–10 per group; analysis using all endpoints (B,F), n = 22–25
per group.
https://doi.org/10.1371/journal.ppat.1008456.g003
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Immune response profiles
Parasite-driven immune responses in chronic L. donovani infections are key mediators of tis-
sue damage [28] and likely have roles in driving cachexia in progressive VL [24]. We therefore
performed expression analysis of spleen and liver tissue at 12 weeks p.i. for a set of genes sus-
pected to be important in hamster VL pathogenesis (Fig 7). Infected hamsters in both groups
displayed strong upregulation of multiple pro-inflammatory mediators as well as counter-reg-
ulatory factors including TGF-β and IL-10, consistent with chronic infection in these tissues.
Analysis of samples from an uninfected, ABX-treated control showed these changes were spe-
cifically induced by the infection (Fig 7). Four genes were differentially expressed between
ABX-treated and untreated infected hamsters: (i) decreased iNOS in the spleen; (ii) increased
IL-1β in the liver; (iii) increased CXCL10 (IP-10) in the liver; and (iv) increased IL-10 in the
liver. These differences in gene expression suggest a subtle but significant shift in the host
response in ABX-treated hamsters. Whether or not these differences contribute to their sur-
vival advantage is not clear.
Fig 4. Prolonged survival in antibiotic treated hamsters is associated with less severe hepatomegaly despite equivalent parasite loads. (A) Liver weights of hamsters
at 12 weeks post-infection (p.i.) with L. donovani and given drinking water containing antibiotic cocktail (ABX) compared with uninfected naïve and untreated controls;
p-values are from one way ANOVA. (B) Pairwise comparison and Pearson correlation test of hepatomegaly severity and change in body weight (proxy for disease
progression) at 12 weeks p.i. (C) Pairwise comparison between hepatomegaly severity and time to humane end-point (fatal progression); p-value is from comparison of
linear regression slope elevations. (D,E) Total parasite loads (D) and infection intensities (E) in livers after 12 weeks of infection, measured by limiting dilution ex vivo
culture assay. (F) Pairwise comparison and Pearson correlation test of liver parasite densities and change in body weight (proxy for disease progression) at 12 weeks p.i.
(G) Pairwise comparison between liver parasite density and time to humane end-point (fatal progression). In B-G data points are for individual hamsters treated with
oral antibiotics (filled circles) and untreated controls (open circles). Analysis using VL onset end point (A,D,E), n = 5–27 per group; analysis using humane/maximum
end-points (C, G), n = 9–10 per group; analysis using all endpoints (B,F), n = 22–25 per group.
https://doi.org/10.1371/journal.ppat.1008456.g004
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PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008456 April 13, 2020 8 / 23
Parasitism of the GI tract and bacterial translocation in progressive
hamster VL
Our analyses of canonical L. donovani target tissues (spleen, liver, bone marrow) did not pro-
vide a clear explanation for the survival advantage seen in ABX-treated hamsters. The GI tract
has previously been reported as a site of L. donovani infection in humans and dogs but is rarely
considered in experimental studies of VL in rodents. We hypothesized that naturally abundant
intestinal myeloid cell populations might support L. donovani infection and that this may be
relevant for the mechanism of protection conferred by oral antibiotics. In support of this, a L.
donovani-specific qPCR assay [29] allowed us to consistently detect parasite DNA in intestinal
tissues and gut-draining lymph nodes from infected hamsters (Fig 8A). Intracellular amasti-
gote forms were readily identifiable in histological sections and were particularly prevalent in
the submucosa of the small intestine and the subcapsular sinus of the lymph node (Fig 8B).
Parasite loads in these sites were equivalent in infected hamsters given ABX and control water
(Fig 8A). Intestinal parasitism was not a feature of acute or chronic infections in mice,
although very low amounts of parasite DNA were detected in the gut-draining lymph nodes
(Fig 8C). This indicates that intestinal infection is a specific feature of progressive VL.
Chronic parasitism of the hamster GI tract by L. donovani led us to question whether its
barrier function might be compromised, potentially leading to bacterial translocation. To test
this, fluorescently-labelled 4 kD dextran was fed to hamsters at 12 weeks post-infection. After
four hours a significant increase in fluorescence was detected in serum from infected hamsters
(Fig 9A). Dextran translocation was not significantly different between the ABX-treated and
untreated animals (Fig 9A), consistent with their similar intestinal parasite loads (Fig 8A). This
suggested that translocation of bacteria from the gut could be a feature of hamster VL. Addi-
tional evidence for this was found in histological sections of the liver and lymph nodes
Fig 5. Leukocyte profiles of dysbiotic hamsters infected with L. donovani. Hamsters were maintained on drinking water with or without antibiotic cocktail (ABX) and
infected with L. donovani (n = 15–19) and compared with naïve (Na) controls (n = 4–5). Data show individual component assays from complete blood counts at 12 weeks
post-infection. Groups were compared by one way ANOVA and differences at p< 0.05 are indicated.
https://doi.org/10.1371/journal.ppat.1008456.g005
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associated with the duodenum, in which Michaelis-Gutmann bodies (MGBs) were found (Fig
9B and 9C). These structures are pathognomonic of malakoplakia, a rare condition most often
seen in urogenital tract infections caused by gram-negative bacteria [30]. It is thought that
MGBs result from mineralisation of macrophages that are defective in their bactericidal activ-
ity. We confirmed the identity of MGBs by staining sections for calcium using alizarin red and
found they were present at a very high frequency in infected hamster livers (Fig 9C and 9D).
These were less abundant on average in hamsters given ABX compared to untreated controls,
though not significantly so (Fig 9F). MGBs were a specific feature of progressive VL because
they were absent from L. donovani-infected mice. These data led us to ask whether secondary
bacterial infection could explain the presence of MGBs. Using immunohistochemical labelling
for a conserved LPS epitope we detected significant levels of this bacterial cell wall component
in L. donovani-infected livers (Fig 9C and 9E). Our hamsters were housed under SPF condi-
tions and LPS was predominantly localised in the areas surrounding blood vessels, so we rea-
soned that the intestinal microbiota was the source of secondary bacterial infection. The
amount of LPS was negatively correlated with lymphocyte frequency (Fig 9F) and positively
correlated with liver inflammation (Fig 9G) leading us to conclude that the staining likely
reflected the presence of live bacteria rather than just LPS. The level of anti-LPS staining was
slightly lower on average in ABX-treated animals’ livers but this difference was not significant
(Fig 9G). This indicates that bacteria resistant to the ABX treatment were able to translocate to
Fig 6. Anaemia and iron sequestration in dysbiotic hamsters infected with L. donovani. Hamsters were maintained on drinking water
with or without antibiotic cocktail (ABX) and infected with L. donovani (n = 15–19) and compared with naïve (Na) controls (n = 4–5). The
erythrocytic compartment was analysed with respect to total red cell count (A), haemoglobin levels (B), haematocrit (C) and mean
corpuscular volume (D). (E) Representative images and quantification of ferric iron content in liver sections stained with Prussian blue
(n = 4–12), magnification 200X, scale bars 50 μm. All data are from 12 weeks post-infection, with mean +SEM and individual hamster data
points shown. Groups were compared by one way ANOVA (A-D) or Kruskal-Wallis test (E) and differences at p< 0.05 are indicated.
https://doi.org/10.1371/journal.ppat.1008456.g006
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the liver to a similar extent to that seen in Ld-infected animals given control water. We readily
isolated live bacteria from liver tissue homogenates under aerobic in vitro growth conditions
(Table 1, S4 Fig) Typing by 16S rRNA amplicon sequencing revealed the presence of nine bac-
terial genera in hamsters from the untreated, infected group compared to five genera for the
ABX-treated group. Paenibacillus and Staphylococcus were suspected as contaminants given
the ubiquity of the former, even in naïve untreated hamsters and the abundance of the latter in
skin and environmental control swab samples (S4 Fig). On average, fewer unique genera were
recovered from individual ABX-treated hamsters than untreated controls, although this was
not statistically significant (Fig 9H). However, by analysing the frequency of each bacterial
genus (Table 1) we found a significant reduction in Rodentibacter (Gram-negative, formerly
Pasteurella [31]) in ABX-treated animals (7 of 11 untreated vs 0 of 6 ABX-treated, p = 0.035).
Streptococcus was also markedly less common, though not to a significant level (7 of 11
untreated vs 1 of 6 ABX-treated, p = 0.13). Interestingly, given the VL anaemia phenotype, hae-
molysis of blood agar was observed for five of the hamster livers testing positive for
Streptococcus.
Our ABX cocktail contained ampicillin and neomycin, which may have had systemic effects
after absorption. To test more directly whether the intestinal microbiota are the source of
Fig 7. Gene expression analysis in dysbiotic hamsters infected with L. donovani. Hamsters were maintained on drinking
water with or without antibiotic cocktail (ABX) and infected with L. donovani (n = 6) or kept naïve (n = 1). At 12 weeks
post-infection, RNA transcript abundance for the indicated genes in spleen and liver tissue was measured by RT-qPCR with
normalisation to Rpl18. Data are mean +SEM log2-transformed fold change in gene expression compared to untreated,
uninfected control hamsters (n = 4). # indicates transcript abundance was below detection limit. Differences are indicated
when p< 0.05 between groups in t-test.
https://doi.org/10.1371/journal.ppat.1008456.g007
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systemic bacterial pathogens we used oral monotherapy with either vancomycin or rifaximin,
whose effects are confined to the intestine. There was no evidence of protection from VL pro-
gression in either monotherapy group: weight profiles, hepatosplenomegaly severity, parasite
loads and anaemia were equivalent to untreated controls (S5 Fig). Live bacteria were still
recovered from these hamsters’ livers. Streptococcus was significantly less frequent in the van-
comycin-treated group but otherwise 16S rRNA sequence profiles were similar to the
untreated controls (S2 Table). Therefore, either the bacterial species relevant to the protection
seen in ABX-treated animals were insensitive to the monotherapies or they do not originate
from the gut, or both.
In summary, these data show that intestinal infection with L. donovani is a feature of severe
progressive VL and this is associated with barrier permeability, translocation of diverse bacte-
ria to the liver and the formation of calcified MGBs. Hamsters treated with a combination of
ampicillin, neomycin and vancomycin were significantly less likely to harbour systemic
Fig 8. The GI tract is a site of chronic L. donovani infection in hamsters but not mice. (A, C) qPCR analysis of L. donovani parasite loads in tissues
from hamsters (A) and mice (C). Parallel reactions for a parasite-specific target (kDNA minicircle) and a host-specific gene (Actbl2) were performed
on DNA extracted from the indicated tissues at 84 days post-infection (dpi) for hamsters (n = 6 per group) and 21 and 84 dpi for mice (n = 3–5 per
group). Lines show medians and dashed line shows the detection limit (mean + 2 standard deviations of uninfected control samples, n = 4). (B)
Histological sections for hamster small intestine (left, centre) and mesenteric lymph node (right) stained with haematoxylin and eosin; arrows indicate
amastigote forms of L. donovani; magnification 400X, scale bars 20 μm.
https://doi.org/10.1371/journal.ppat.1008456.g008
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Rodentibacter than untreated controls, indicating that these bacteria might contribute to the
fatal progression of VL in the hamster model.
Fig 9. Evidence of bacterial co-infection in hamster visceral leishmaniasis. (A) Naïve or L. donovani (Ld) infected hamsters maintained on drinking water with or
without antibiotic cocktail (ABX) were fed fluorescently-labelled 4 kDa dextran at 12 weeks post-infection (wpi). After 4 hours the intensity of fluorescence in serum
samples was measured as an indicator of intestinal barrier leakiness. (B) Histological sections stained with haematoxylin and eosin showing presence of Michaelis-
Gutmann bodies (MGBs, white arrows) in L. donovani infected liver and duodenal lymph node tissue, black arrow indicates intracellular amastigotes. (C) Quantification
of MGB abundance at 12 wpi. (D) Histological liver sections stained with haematoxylin and eosin (left), alizarin red for calcium detection (centre) and
immunohistochemical (IHC) detection of bacterial endotoxin (right), white arrows indicated MGBs, black arrow indicates intracellular amastigotes, asterisks indicate
anti-endotoxin IgG-reactive areas. Image magnifications and scale bars are 400X and 20 μm (C), 12.5X and 1 mm (D, H&E, upper), 40X and 200 μm (D, H&E, upper)
100X and 500 μm (alizarin), 400X and 30 μm (IHC). (E) Quantification of anti-endotoxin IgG-reactive areas at 12 wpi. (F,G) Pairwise comparison and Pearson
correlation tests of liver endotoxin content and peripheral blood lymphocyte frequency (F, n = 10) and liver inflammation scores (G, n = 28). (H) Quantification of
unique bacterial genera present in liver tissue assessed by 16S rDNA sequencing. Data are for male hamsters. Data on charts (A,C,E,H) are means +SEM, compared by
one-way ANOVA, n = 3–12.
https://doi.org/10.1371/journal.ppat.1008456.g009
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Discussion
A largely neglected area of investigation pertaining to the variable clinical outcomes in individ-
uals infected with L. donovani is the influence of the host’s microbiota in preventing or pro-
moting VL pathogenesis. We have used the hamster model of VL, which mimics some key
clinicopathological features of active human disease, to explore the effect of intestinal dysbiosis
on the course of disease. L. donovani-infected hamsters that were maintained on broad spec-
trum antibiotics in their drinking water had delayed onset of weight loss, reduced hepatosple-
nomegaly, and significantly improved nine-month survival compared to untreated controls.
Strikingly, the protection in the dysbiotic hamsters was not associated with lower visceral para-
site burdens. Progressive disease was associated with intestinal parasitism, compromised bar-
rier function, and evidence for translocation of live bacteria to the liver. The findings are the
first to directly link the host microbiota to clinical outcome and to show the benefits of antimi-
crobial therapy in the treatment of VL.
Our findings extend the evidence base that hamsters are a suitable model of symptomatic
human VL. Specifically, we draw attention to the potential importance of a gut-liver axis in dis-
ease pathogenesis. The liver is well established as a site of non-resolving L. donovani infection
in hamsters and humans, in contrast to the largely asymptomatic mouse model. Features of
hepatic pathology included severe chronic granulomatous inflammation, malakoplakia and
iron sequestration, which were all absent from the mouse model. Our data unequivocally show
that parasitism of the intestine is a feature of hamster and not murine VL. This site is rarely
studied in rodent models although infections have previously been described for L. braziliensis
[32] and L. donovani [33]. Intestinal parasitism and symptoms are common in canine VL
caused by L. infantum [34, 35]. Some data indicate that the gut is an important site of parasite
persistence in human VL. Anorexia, abdominal pain and weight loss are all symptoms of acute
infection with L. donovani; symptomatic gastrointestinal leishmaniasis is relatively common in
immunosuppressed and HIV co-infected patients [36], and there are occasional reports of dis-
covery of Leishmania parasites in the GI tracts of immunocompetent individuals [37, 38].
Against this background, our data suggest that intestinal parasitism is likely to be more com-
mon and more important to VL outcomes than previously thought.
Secondary bacterial infections in VL have been attributed to environmental and nosocomial
sources or to underlying infections such as tuberculosis [39–41]. Our findings for hamsters
Table 1. Frequency of live bacterial genera isolated from hamster liver homogenates.
Genus Naïve Ld1S Infected
Not Treated (n = 4) Not Treated (n = 11) ABX treated (n = 6)
Frequency 95% CI Frequency 95% CI Frequency 95% CI p
Paenibacillus 1.000 (1–0.51) 0.727 (0.902–0.434) 0.833 (0.991–0.436) >0.999
Streptococcus 0.000 (0.489–0) 0.636 (0.848–0.353) 0.167 (0.563–0.008) 0.131
Granulicatella 0.250 (0.699–0.012) 0.273 (0.565–0.097) 0.000 (0.39–0) 0.515
Bacillus 0.000 (0.489–0) 0.091 (0.377–0.004) 0.167 (0.563–0.008) >0.999
Rodentibacter 0.250 (0.699–0.012) 0.636 (0.848–0.353) 0.000 (0.39–0) 0.035
Lactobacillus 0.000 (0.489–0) 0.091 (0.646–0.151) 0.333 (0.39–0) 0.515
Staphylococcus 0.250 (0.699–0.012) 0.364 (0.646–0.151) 0.000 (0.39–0) 0.237
Actinomyces 0.000 (0.489–0) 0.091 (0.377–0.004) 0.000 (0.39–0) >0.999
Escherichia 0.250 (0.699–0.012) 0.182 (0.476–0.032) 0.000 (0.39–0) 0.515
Klebsiella 0.000 (0.489–0) 0.000 (0.258–0) 0.333 (0.7–0.059) 0.110
Morganella 0.000 (0.489–0) 0.000 (0.258–0) 0.000 (0.39–0) >0.999
Proteus 0.000 (0.489–0) 0.000 (0.258–0) 0.000 (0.39–0) >0.999
https://doi.org/10.1371/journal.ppat.1008456.t001
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kept in a highly controlled, pathogen-free environment raise the possibility that a patient’s
endogenous microbiota also needs to be considered. Our data indicated that Rodentibacter are
prime candidates contributing to hamster VL progression. This genus includes rodent patho-
biont species that can cause opportunistic infections, septicaemia and severe pneumonia [42,
43]. L. donovani infection of the intestinal mucosa may be directly related to the increased gut
barrier permeability observed during progressive disease, similar to that produced by entero-
pathogens and other systemic infections (reviewed in [44]). We obtained direct evidence for
compromised barrier integrity in VL from the elevated serum levels of orally administered
fluorescently-labelled 4 kDa dextran. The perivascular staining of LPS in the liver was also con-
sistent with bacterial translocation from the gut, as was the presence of MGBs, which comprise
calcified macrophages containing partially digested bacteria. The lack of impact by non-
absorbed antibiotics indicates that the protection conferred by ABX treatment is probably
mediated by ampicillin and/or neomycin activity against bacteria in sites other than the intesti-
nal lumen. This could be either via redistribution of the drug(s) after absorption or via direct
action in the naso/oropharynx. Rodentibacter can be found in the intestine, but are more com-
monly known to colonise the upper respiratory tract and oral cavity [45, 46]. Human mucosal
leishmaniasis caused by L. dononvani is well known, particularly in Sudan from where the
Ld1S strain originates [47–51]. Future experimental studies should therefore test whether L.
donovani persists in the hamster respiratory tract and mucocutaneous tissues, where it may
promote translocation of bacterial pathobionts such as Rodentibacter.
While these are the first observations of their kind in an animal model of VL, a series of
clinical findings support a role for bacterial translocation in human VL [52, 53]. In these stud-
ies of Brazilian VL patients, including those with HIV co-infection, augmented levels of plas-
matic LPS were observed that positively correlated with upregulated expression of pro-
inflammatory cytokines and cellular activation markers, responses that over time were argued
to result in T cell depletion and exhaustion (reviewed in [54]). A strikingly pro-inflammatory
environment has been described in livers and spleens of L. donovani infected hamsters by tran-
scriptional profiling [13, 55]. Our results are largely consistent with those findings, with tran-
scripts for selected inflammatory mediators, e.g. IFNγ, TNFα, IL-1β, CXCL10, showing strong
upregulation, particularly in the liver, though upregulation of counter-regulatory cytokines,
eg, IL-10, TGFβ, was also observed. The ABX-treatment group did show significantly
increased levels of IL-10 in the liver, which could have a tissue-protective effect. On the whole
though, differences in immune response profiles were moderate and possibly too selective to
meaningfully attribute their survival benefit to attenuation of a bacteria-driven cytokine storm
within the spleen or liver.
The hamster is an outbred animal model and we observed high intra-group variability in
many of our data sets. Consequently, our sample sizes had limited statistical power to detect
moderate effects. For example, many of our assays were carried out at 12 weeks post-infection
and at this time point there was a wide range of progression rates (in terms of weight loss)
within both experimental groups. With the possible exception of reduced hepatosplenomegaly,
our analyses of parasite loads, pathology and immune responses in multiple tissues at this time
point failed to identify specific factors that were sufficiently different in ABX-treated hamsters
to explain their slow progression phenotype. Conversely, our analyses on humane end-point
samples, taken from animals that had reached the same stage of progression (over largely vari-
able time periods), were of limited value for establishing an upstream mechanism. The main
protective effect in treated hamsters could be attributed to the absence of rapid progression,
which occurred in approximately half of untreated controls. Therefore, analysis of additional
time points with larger animal cohorts could aid future investigation of this phenomenon.
Other factors that were not part of our study could also be relevant. For example, long-term
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antibiotic-induced dysbiosis may have nutritional consequences such as caloric restriction or
altered availability of micro-nutrients. However, this seems an unlikely explanation for the
observed protection because malnutrition is well-established as a risk factor in human VL
[10]. Furthermore, although we were able to type some bacterial genera in the VL affected
liver, it may be that critical species were not viable under the culture conditions that we used.
Our method of monitoring the effect of antibiotics using 16S rRNA on faecal pellets was faeces
may not accurately represent the effect of antibiotics on the small intestinal flora. Metage-
nomic sequencing strategies may reveal additional candidate bacterial species involved in
accelerating VL progression.
Bacterial sepsis is a leading cause of death in VL but appropriate antibiotic treatment may
not be initiated until a culture-positive diagnostic test result is obtained [40, 56, 57]. There are
reports that antibiotic prophylaxis is already used in some endemic areas as an adjunct to anti-
parasitic drug therapy for VL [58]. Our data provide support for efforts to obtain empirical evi-
dence that this approach has clinical benefit for VL patients.
Materials and methods
Ethics statement
All experiments were performed in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the NIH. The protocols were approved by the
Animal Care and Use Committee of the NIAID (protocol LPD 68E). Animals were euthanised
by CO2 inhalation.
Animals
C57BL/6 mice were bred in-house and Golden Syrian hamsters were bought from Harlan Lab-
oratories (Indianapolis, IN). They were maintained under specific pathogen-free conditions in
in the animal care facility of the National Institute of Allergy and Infectious Diseases (NIAID),
National Institutes of Health (NIH). They experienced a 12 hour light/dark cycle and had
access to food and water ad libitum. Female mice were used at age 8–10 weeks. Female and
male hamsters were used at age 4–6 weeks. The primary humane end point was loss of 20% of
body weight compared to the start of infections. Secondary humane end points included sus-
tained lethargy or absence of feeding or drinking behaviour.
Antibiotics
To induce intestinal dysbiosis, animals were given ad libitum water containing ampicillin (1
mg/ml), neomycin (1 mg/ml) and vancomycin (0.5 mg/ml) (“ABX”), or in some cases vanco-
mycin only. In some experiments hamsters were given rifaximin (100 mg/kg) in Ora-Blend
vehicle (Perrigo) p.o. three times per week. In some experiments with C57BL/6 mice, metroni-
dazole (1 mg/ml) and sucralose (3 mg/ml) was included in the ABX cocktail. Antibiotic-con-
taining water was replaced weekly. Treatment was initiated 4 weeks prior to L. donovani
infection and sustained throughout the experiments.
Parasites and infections
In vitro promastigote cultures of the L. donovani strain 1S (MHOM/SD/00/1S-2D) were estab-
lished from frozen stocks of tissue amastigotes at 26˚C in medium 199 supplemented with
20% heat-inactivated fetal calf serum, 100 U/mL penicillin, 100 mg/mL streptomycin, 2 mM
L-glutamine, 40 mM Hepes, 0.1 mM adenine (in 50 mM Hepes), 5 mg/mL hemin (in 50%
triethanolamine), and 1 mg/mL 6-biotin (M199/C). Minimally passaged promastigotes were
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seeded at 5x105 /ml and 5–6 days later metacyclic promastigotes were purified by centrifuga-
tion through a Ficoll gradient [59]. Hamsters were infected by intracardiac injection while
under gaseous anaesthesia (2% isoflurane in oxygen) with 3 × 107 metacyclic promastigotes.
Mice were infected by intravenous injection with 1x107 metacyclic promastigotes.
Necropsies
Animals were euthanised by CO2 inhalation. This was followed by cardiac exsanguination and
trans-cardial perfusion with 10 ml (mice) or 20 ml (hamsters) PBS. Spleens, livers, caeca, small
and large intestines, mesenteric lymph nodes and femurs were collected as required. Tissue
fragments were weighed and either snap-frozen on dry ice, fixed in 10% neutral buffered for-
malin or transferred to ice cold M199/C media.
Parasite loads—ex vivo titrations
Parasite loads in livers, spleens and bone marrow were determined using an ex vivo limiting
dilution assay [60]. Briefly, organs were dissociated by mashing through a 70 μm cell strainer
and femurs were flushed with M199/C media, then cells were collected by centrifugation at
3000 x g for 15 mins. The cell pellet was washed in media, centrifuged again and then erythro-
cytes were lysed by incubation for 5 mins in ACK buffer (Lonza, USA). Cells were washed
with excess PBS, harvested by centrifugation and re-suspended in M199/C. Duplicate two-fold
dilution series to extinction were made in M199/C in 96 well culture plates (Nunc). The cul-
ture plates were sealed with parafilm, and incubated at 27˚C. After 21 days, all wells were
examined microscopically and scored for L. donovani promastigote growth. The number of
parasites per organ was extrapolated from the number of parasite positive wells.
Quantitative PCR for parasite loads
For DNA extraction, frozen tissue samples were thawed and immediately homogenized in at
least 400 μl lysis buffer (4M urea, 200 mM Tris, 20 mM NaCl, 200 mM EDTA, pH 7.4) per 50
mg tissue using a Precellys 24 instrument (Bertin). The tissue suspension was then incubated
overnight at 37˚C with 0.6 mg proteinase K in a shaking incubator. DNA was extracted using
the High Pure PCR Template Preparation Kit (Roche) according to the manufacturer’s
instructions. Real-time PCR reactions were prepared using the SensiFAST SYBR Kit (Bioline)
and run on an ABI Prism 7900HT or QuantStudio6 instrument (Applied Biosystems) using an
annealing temperature of 59˚C. Reactions were run in duplicate and contained 10–100 ng
DNA and 0.2 μM of each primer. Separate reactions were performed to quantify L. donovani
using primers targeting kDNA minicircles and mouse or hamster DNA using conserved prim-
ers targeting the actbl2 gene. Primer sequences were as follows: kDNA-F CTTTTCTGGT
CCTCCGGGTAGG, kDNA-R CCACCCGGCCCTATTTTACACCAA [29], ACTBL2-F
AAGGACTGTTATGTGGGAG and ACTBL2-R GTGTGGTACCAGATCTTCTC. Measure-
ments of L. donovani and mouse/hamster DNA content were established using standard
curves.
Quantitative PCR for bacterial 16S rDNA
DNA was extracted from frozen faecal pellets using the QIAamp DNA Stool Mini Kit accord-
ing to the manufacturer’s instructions with modification whereby pellets were incubated in
lysis buffer overnight in a shaking incubator. Real-time PCR reactions were prepared using the
SensiFAST SYBR Kit (Bioline) and run on an ABI Prism 7900HT or QuantStudio6 instrument
(Applied Biosystems) using an annealing temperature of 63˚C. Reactions were run in duplicate
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and contained 10–100 ng DNA and 0.2 μM of primers F340 (ACTCCTACGGGAGGCAGCA
GT) and R514 (ATTACCGCGGCTGCTGGC) [61]. A full length 16S rDNA sequence was
PCR amplified and cloned into pCR2.1 using the TA Cloning kit (Invitrogen). A dilution series
of the resulting plasmid, pCR2.1-16S, was used as a standard curve to establish 16S rDNA copy
number in faecal samples.
Quantitative PCR for immune response gene expression
Frozen tissue samples were thawed and immediately homogenized in at least 400 μl Tri-
reagent (SigmaAldrich) per 50 mg tissue using a Precellys 24 instrument (Bertin) then mixed
with 0.2 volumes of chloroform. The aqueous phase was separated by centrifugation at 12000 x
g and then processed using the RNeasy kit (Qiagen) with on-column DNAse I treatment.
cDNA synthesis reactions were prepared using 1 μg RNA and the SuperScript III first-strand
synthesis system for reverse transcription (Invitrogen). Real-time PCR reactions were pre-
pared using the SensiFAST SYBR Kit (Bioline) and run on a QuantStudio6 instrument
(Applied Biosystems) using an annealing temperature of 60˚C. The relative expression level of
each gene was determined by the comparative CT method [62] using rpl18 as the endogenous
control gene. Primer sequences are given in S1 Table.
Hematology and serology
Automated complete blood counts were conducted by the NIH Department of Laboratory
Medicine hematology service. Leishmania-specific IgG serum titres were determined by
ELISA using total soluble leishmania antigen (SLA). In brief, Immunol 4X HB plates (Thermo-
Fisher) were coated with 20μg/ml SLA in carbonate-bicarbonate coating buffer overnight.
Plates were blocked with 4% BSA before washing and adding diluted sera. After washing, an
anti-hamster IgG ALP (Sigma Aldrich) secondary antibody in conjunction with pNPP were
used to detect bound anti-Leishmania antibody. To test intestinal barrier permeability, ham-
sters were fasted for 12 hours then orally dosed with 50 mg FITC-labelled 4 kDa dextran
(Sigma). After four hours blood was collected, allowed to clot and serum was then isolated.
Fluorescence in serum samples and a standard curve was measured in a plate reader (Molecu-
lar Devices) with filters for excitation at 485 nm and emission at 528 nm.
Histopathology and immunohistochemistry
Tissue samples were fixed in neutral buffered 10% formalin for 24–72 hours, then dehydrated,
cleared and embedded in paraffin. For general histopathological assessment, performed by a
board-certified veterinary pathologist, three micron sections were stained with haematoxylin
and eosin. An inflammation index was derived by quantifying the number of nuclei in these
stained sections. For calcium detection sections were stained with alizarin red for 2 mins,
washed in running water then dehydrated in acetone, followed by 50% acetone in xylene (vol/
vol). For iron detection, sections were treated with 20% hydrochloric acid and 10% potassium
ferrocyanide for 20 mins and then counterstained with nuclear fast red for 3 minutes. Bacterial
endotoxin content was quantified using immunohistochemistry. For this, sections were sub-
jected to heat-induced epitope retrieval by incubation in 10 mM sodium citrate, 0.05%
Tween20 for 30 mins, then cooled and rinsed in distilled water. Sections were blocked with
10% sheep serum and 1% BSA in TBS for 30 mins then incubated at 4˚C overnight with 2 μg/
ml monoclonal mouse anti-core LPS IgG (Hycult) and 1% BSA in TBS. Sections were then
washed with 0.025% Triton X-100 in TBS and endogenous peroxidase activity was quenched
with 3% H2O2 for 30mins. Bound primary antibody was labelled with 6 μg/ml biotinylated
goat anti-mouse IgG and 1% BSA in TBS for 30 mins. Slides were then washed as previously,
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incubated with avidin-peroxidase (Vectalabs) for 30 mins, washed again and treated with DAB
(Thermo) for 5 mins. Sections were counterstained with haematoxylin and mounted with
DPX. For quantification of histological and immunohistochemical stains and features, images
of five (alizarin) or ten (all other stains) fields of view were acquired using a camera (Leica
DFC295) attached to a Leica DM3000 LED microscope. Images were digitized for histomor-
phometric analysis using the Leica Application Suite V4.5 software (Leica).
Bacterial growth and 16S rDNA sequence typing
Liver tissue samples were stored in PBS on ice then transferred to a gentleMACS tube contain-
ing 3–10 ml PBS and homogenized using a gentleMACS dissociator (Miltenyi Biotec).
Homogenate aliquots were spread onto three agar plates (Teknova) comprising (i) trypticase
soy agar (TSA) + 0.1% w/v Tween-80, (ii) TSA + 5% v/v Sheep’s blood, and (iii) brain heart
infusion agar. Plates were incubated for 24–48 hrs. If bacterial colonies were visible then a rep-
resentative sample of the morphologies present was picked into nutrient-matched broth and
incubated overnight with shaking at 225 rpm. DNA was extracted using the DNeasy Blood
and Tissue kit (Qiagen) according to the manufacturer’s protocol, including the recommended
pre-treatment steps for Gram-positive bacteria. 16S rDNA amplicons were generated by PCR
using primers 27F (5’-AGAGTTTGATCMTGGCTCAG-3’) and 1492R: (5’- GGTTACCTT
GTTACGACTT-3’) [63]. Consensus sequences for each amplicon were generated commer-
cially (Eurofins genomics) and aligned against 16S rDNA reference sequences (NCBI) by
BLAST to identify genera.
Statistics
Individual animals were used as the unit of analysis, except where otherwise stated. No blind-
ing or randomisation protocols were used. Statistical differences between groups were evalu-
ated using the Mann-Whitney U test, one-way ANOVA with Sidak’s post-hoc correction for
multiple comparisons, or the Kruskal-Wallis test with Dunn’s post-hoc correction. Pearson
and Spearman log-rank correlation analyses were used to evaluate relationships between nor-
mally distributed and non-normally distributed variables respectively. Survival curves were
compared by Gehan-Breslow-Wilcoxon test. Bacterial genus frequencies were compared using
Fisher’s exact test. These tests were performed in GraphPad Prism v.7. Differences of p< 0.05
were considered significant.
Supporting information
S1 Table. RT-qPCR primers used in the study.
(PDF)
S2 Table. Frequency of live bacterial genera recovered from livers of L. donovani-infected
hamsters treated with vancomycin or rifaximin.
(PDF)
S1 Fig. Comparison of VL related weight profiles for male and female hamsters.
(TIF)
S2 Fig. Pairwise comparisons of spleen and liver total parasite loads with VL progression.
(TIF)
S3 Fig. Bone marrow parasite loads and pairwise comparison with disease progression.
Parasite loads were quantified by limiting dilution in vitro culture assay.
(TIF)
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S4 Fig. Analysis of 16S rRNA genetic diversity for live bacteria present in hamster liver tis-
sue samples, skin swabs and environment.
(TIF)
S5 Fig. Evaluation of the impact of oral vancomycin or rifaximin monotherapy on hamster
VL outcomes.
(TIF)
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